Hishar Hassan, Muhammad Faiz Othman and Hairil Rashmizal Abdul Razak*
Bone metastases are a common source of malignancy in the skeleton and occur much more often than primary bone cancer. Several works were ongoing to identify early markers for bone metastasis and novel drug targets to improve patients' quality of life. As some concerns exist with the [18F]sodium fluoride in positron emission tomography (PET) bone imaging, there has been an increase in the number of targeted radiopharmaceutical markers for bone metastases imaging in its competitor, 68Ga. Since 18F properties are superior to those of 68Ga, there is a distinct motivation for developing 18F radiopharmaceuticals for bone metastases imaging.
bone metastasis, bone imaging, positron emission tomography (PET), single-photon emission tomography (SPECT), bisphosphonate, radiopharmaceutical
Centre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia, 43400 Serdang, Selangor, Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, 42300 Bandar Puncak Alam, Selangor, Department of Radiology, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor